These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 33552467)

  • 1. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews.
    Pelletier R; Ng K; Alkabbani W; Labib Y; Mourad N; Gamble JM
    Ther Adv Drug Saf; 2021; 12():2042098621989134. PubMed ID: 33552467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of sodium-glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews.
    Pelletier R; Ng K; Alkabbani W; Labib Y; Mourad N; Gamble JM
    Endocrinol Diabetes Metab; 2020 Jul; 3(3):e00145. PubMed ID: 32704566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
    Li CX; Liu LY; Zhang CX; Geng XH; Gu SM; Wang YQ; Liu H; Xie Q; Liang S
    Front Endocrinol (Lausanne); 2023; 14():1238399. PubMed ID: 37701900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
    Chen L; Xue Q; Yan C; Tang B; Wang L; Zhang B; Zhao Q
    Front Endocrinol (Lausanne); 2023; 14():1256548. PubMed ID: 38027214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51 713 individuals.
    Huang CY; Lee JK
    Diabetes Obes Metab; 2020 Dec; 22(12):2348-2355. PubMed ID: 32744411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
    Donnan JR; Grandy CA; Chibrikov E; Marra CA; Aubrey-Bassler K; Johnston K; Swab M; Hache J; Curnew D; Nguyen H; Gamble JM
    BMJ Open; 2019 Feb; 9(1):e022577. PubMed ID: 30813108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.
    Puckrin R; Saltiel MP; Reynier P; Azoulay L; Yu OHY; Filion KB
    Acta Diabetol; 2018 May; 55(5):503-514. PubMed ID: 29484489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience.
    Islam L; Jose D; Alkhalifah M; Blaibel D; Chandrabalan V; Pappachan JM
    World J Diabetes; 2024 Mar; 15(3):463-474. PubMed ID: 38591092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
    Kinduryte Schorling O; Clark D; Zwiener I; Kaspers S; Lee J; Iliev H
    Adv Ther; 2020 Aug; 37(8):3463-3484. PubMed ID: 32372290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies.
    Li CX; Liu TT; Zhang Q; Xie Q; Geng XH; Man CX; Li JY; Mao XY; Qiao Y; Liu H
    Front Pharmacol; 2023; 14():1275060. PubMed ID: 37905204
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety of Sodium-Glucose Co-Transporter 2 Inhibitors.
    McGill JB; Subramanian S
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S45-S52. PubMed ID: 31741440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
    Li D; Wang T; Shen S; Fang Z; Dong Y; Tang H
    Diabetes Obes Metab; 2017 Mar; 19(3):348-355. PubMed ID: 27862830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials.
    Dicembrini I; Tomberli B; Nreu B; Baldereschi GI; Fanelli F; Mannucci E; Monami M
    Diabetes Res Clin Pract; 2019 Jul; 153():138-144. PubMed ID: 31150722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
    Lu J; Tang L; Meng H; Zhao J; Liang Y
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3169. PubMed ID: 30974510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?
    Khouri C; Cracowski JL; Roustit M
    Diabetes Obes Metab; 2018 Jun; 20(6):1531-1534. PubMed ID: 29430814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse effects and safety of SGLT-2 inhibitors.
    Halimi S; Vergès B
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S28-34. PubMed ID: 25554069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
    Schwartz SS; Ahmed I
    Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.